Semaglutide and related weight-loss medications, known as GLP-1 agonists, may slow biological ageing, reduce inflammation, improve cognitive function and gut health, and reduce alcohol use in people living with HIV, according to studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
“While we know some of the types of benefits [related to] metabolic health, this new data points to potential ageing benefits,” said Dr Michael Corley of the University of California San Diego, the lead investigator for one of the studies. “It suggests that GLP-1 agonists may be helpful in stabilising biological ageing in a subset of people living with HIV.”
Weight gain and metabolic abnormalities are a growing concern for people with HIV as they get older. Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (sold as Ozempic or Wegovy), mimic a natural hormone that suppresses appetite, regulates insulin and blood sugar, and slows emptying of the stomach. Originally developed to treat type 2 diabetes, these drugs are now widely used to manage obesity. They have been shown to reduce the risk of heart and kidney disease and some types of cancer, and they are being studied for fatty liver disease, Alzheimer’s disease and other conditions.
Read the full news story at aidsmap.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.